Predictive survival markers in patients with surgically resected non-small cell lung carcinoma

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1125-1134

  Moldvay, Judith ^a   Scheid, Philippe ^a,b   Wild, Pascal ^b   Nabil, Karim ^a   Siat, Joëlle ^b   Borrelly, Jacques ^b   Marie, Béatrice ^b   Farré, Guillaume ^a   Labib, Taoufik ^a   Pottier, Gérard ^a   Sesboüé, Richard ^a   Bronner, Christian ^a   Vignaud, Jean Michel ^b   Martinet, Yves ^b   Martinet, Nadine ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; HLA ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ABO BLOOD-GROUP SYSTEM; ADENOCARCINOMA; AGED; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CODON; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RAS PROTEINS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034100054     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. El-Torky, M., El-Zeky, F., and Hall, J. Significant changes in the distribution of histology types of lung cancer: a review of 4928 cases. Cancer (Phila.), 65: 2361-2367, 1990.
2. Dev, D., Capewell, S., Sankaran, R., Lamb, D., and Sudlow, N. F. Adenocarcinoma of the lung. Clinical features and survival. Respir. Med., 90: 333-337, 1996.
3. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N. M., and Rabbits, P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene, 7: 1989-1997, 1992.
4. Kishimoto, Y., Sugio, K., Hung, J., Virmani, A. K., McIntire, D., Minna, J. D., and Gazdar, A. Allele specific loss in chromosome 9 p loci in preneoplastic lesions accompanying non-small cell lung cancers. J. Natl. Cancer Inst., 87: 1224-1230, 1995.
5. Strauss, G. M. Prognostic markers in resectable non-small cell lung cancer. Hematol. Oncol. Clin. North Am., 11: 409-434, 1997.
6. Mountain, C. F. A new international staging system for lung cancer. Chest, 89: 225S-233S, 1986.
7. World Health Organization. Histological Typing of Lung Tumors, 2nd ed. Geneva: World Health Organization, 1981.
8. Plenat, F., Picard, E., Antunes, L., Vignaud, J-M., Marie, B., Chalabreysse, P., and Muhale, F. L'amplification des réactions immunologiques par dépôt catalytique aux sites de réactions de dérivés de la tyramine. Ann Pathol., 1: 17-23, 1997.
9. Flehinger, B. S., Kimmel, M., and Melamed, M. R. The effect of surgical treatment on survival from early lung cancer; Implication for screening. Chest, 101: 1013-1018, 1992.
10. Harpole, D. H., Herndon, J. E., Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I NSCLC utilizing presentation, histopathology and oncoprotein expression. Cancer Res., 55: 51-56, 1995.
11. Jiang, S. X., Sato, Y., Kuwao, S., and Kameya, T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol., 177: 135-138, 1995.
12. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. M. Bcl-2 protein in non-small cell lung carcinoma. N. Engl. J. Med., 529: 690-694, 1993.
13. Ohsaki, Y., Toyoschima, E., Fujiuchi, S., Matsui, H., Hirata, S., Miyokawa, N., Kubo, Y., and Kikuchi, K. Bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin. Cancer Res., 2: 915-920, 1996.
14. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C. A., Basolo, F., and Bevilacqua, G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br. J. Cancer, 71: 1003-1007, 1995.
15. Reed, J. C. Double identity for proteins of the bcl-2 family. Nature (Lond.), 387: 773-776, 1997.
16. Koukourakis, M. I., Giatromanolaki, A., O'Byrne, K. J., Whitehouse, R. N., Talbot. D. C., Gatter, K. C., and Harris, A. L. Potential role of Bcl-2 as a suppressor of tumor angiogenesis in non-small cell lung cancer. Int. J. Cancer, 74: 565-570, 1997.
17. Oriol, R., Le pendu, J., and Mollicone, R. Genetics of ABO, H. Lewis X and related antigens. Vox Sang., 51: 161-171, 1986.
18. Lee, J. S., Ro, J. Y., Sahin, A. A., Hong, W. K., Brown, B. W., Mountain, C. F., and Hittelman, W. N. Expression of blood-group antigen A: A favorable prognostic factor in non-small cell lung cancer. N. Engl. J. Med., 324: 1084-1090, 1991.
19. Matsumoto, H., Muramatsu, H., and Shimotakahra, T. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer (Phila.), 72: 75-81, 1993.
20. Martinet, Y., Brambilla, E., Martin, J-P., Martinet, N., and Vignaud, J-M. Biological basis of lung cancer prevention. Med. Sci., 13: 1465-1471, 1997.
21. Greatens, T. M., Nighans, G. A., Rubins, J. B., Jessuru, N. J., Kratzke, R. A., Maddaus, M. A., and Niewoehnel, D. E. Do molecular markers predict survival in NSCLC? Am. J. Respir. Crit. Care Med., 157: 1093-1097, 1998.
22. Ogawa, J. I., Inoue, H., and Koide, S. Expression of a-1,3-fucosyl-transferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res., 56: 325-329, 1996.
23. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, A., and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.
24. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, A., Gazdar, A. F., and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-499, 1989.
25. Nishio, M., Koshikawa, T., and Kuroishi, T. Prognostic significance of abnormal p53 accumulation in primary resected NSCLC. J. Clin. Oncol., 14: 497-502, 1996.
26. Kern, J. A., Slebos, R. J. C., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., and Schwartz, A. C-erB-2 expression and codon 12 k-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest., 93: 516-520, 1994.
27. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S., and Sugimachii, K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell lung carcinoma. Eur. J. Cancer, 27: 1372-1375, 1991.
28. Giatromanolaki, A., Gorgoulis, V., Chetty, R., Koukourakis, M. I., Whitehouse, R., Kittas, C., Veslemes, M., Garter, K. C., and Iordanoglou, I. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res., 16: 987-994, 1996.
29. her-2 in patients with systemically untreated non-small cell lung cancer: an immunohistochemical study on cryosections. Br. J. Cancer, 74: 86-91, 1996.
30. Slebos, R. J. C., Kibbelaar, R. E. O., Dalesio, A., Kooistra, A. J., Stam, C. J. L., Meijer, M., Wagenaar, R. G., Vanderschueren, J. R. A., Zandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. Ki-RAS oncogene activation as a prognosis marker in adenocarcinoma of the lung. N. Engl. J. Med., 10: 561-565, 1990.
31. Suzuki, Y., Orita, M., Shiraisi, M., Hayashi, K., and Sekiya, T. Detection of ras gene mutations in human lung cancers by single strand conformational polymorphism analysis of polymerase chain reaction products. Oncogene, 5: 1037-1043, 1990.
32. Rosell, R., Li, S., Skacel, Z., Mate, J. L., Maestre, J., Canela, M., Tolosa, E., Armengol, P., Barnadas, A., and Ariza, A. Prognostic impact of mutated k-ras gene in surgically resected non small cell lung cancer patients. Oncogene, 8: 2407-2412, 1993.
33. Reynolds, S. H., Anna, C. K., Brown, K. C., Wiest, J. S., Beattie, E. J., Pero, R. W., Iglehart, J. D., and Anderson, M. W. Activated proto-oncogenes in human lung tumors from smokers. Proc. Natl. Acad. Sci. USA, 88: 1085-1089, 1991.
34. Clements, N. C., J. R., Nelson, M. A., Wymer, J. A., Savage, C., Aguire, M., and Garewal, H. Analysis of K-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy. Am. J. Respir. Crit. Care Med., 152: 1374-1378, 1995.
35. Rosell, R., Monzo, M., Pifarre, A., Ariza, A., Sanchez, J. J., Moreno, I., Maurel, J., Lopez, M. P., Abad, A., and Maria de Anta, J. Molecular staging of NSCLC according to K-ras genotypes. Clin. Cancer Res., 2: 1083-1086, 1996.
36. Harada, M., Dosaka-Akita, H., Miyamoto, H., Kuzumaki, N., and Kawakami, Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer (Phila.), 69: 72-77, 1992.
37. Klein, N., Vignaud, J-M., Sadmi, M., Plenat, F., Borrelly, J., Duprez, A., Martinet, Y., and Martinet, N. Squamous metaplasia expression of proto-oncogenes and p53 in lung cancer patients. Lab. Invest., 68: 26-32, 1993.
38. Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Jr., Herndon, J. E., II, Shieh, D. B., Richards, P., Blanco, R., Xu, H. J., Strauss, G. M., and Sugarbaker, D. J., Molecular pathologic substaging in 244 stage I Non-small-cell lung cancer patients: Clinical implications. J. Clin. Oncol., 16: 2468-2477, 1998.